Researchers at Saint Louis University School of Medicine investigated differences in T-cell responses between male and female patients with lung cancer that may help direct future treatments.
HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...
Turns out, Walker is one tough dude, though, so “a while,” turned out to be all of two days. All he did between his last post ...
WVU Medicine Barnesville Hospital and WVU Medicine Harrison Community Hospital are now certified members of the WVU Cancer ...
The Navy said the service's top admiral is "cancer-free" after surgery last summer and follow-up radiation therapy.
McLeod Health celebrated a decade of its HOPE Fund in Florence. The fund connects people to resources they need to help with ...
BAY 2927088, an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, led to promising response rates when used for the treatment of patients with pretreated HER2 ...
Being told you have cancer is like a dark cloud over your life. It’s tough, no matter the type of cancer. Every day feels ...
Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...
Hetronifly in combination with chemotherapy was shown to improve survival of patients with extensive stage small cell lung ...
ThePrint on MSN1d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catchIn head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback